Agile Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Agile Therapeutics

11/08/2022 22:48

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly
adjusted
loss of $2.71​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of $3.70 per share.
    * Revenue rose 79.4% to $2.13 million from a year ago;
analysts
expected $1.98 million. 
    * Agile Therapeutics Inc's reported EPS for the quarter was
a loss
of $2.71​.
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Agile Therapeutics Inc shares had fallen by 45.5% this
quarter and lost 96.8% so far this year.
    * The company reported a quarterly loss of $12.22 million.
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 09:48 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -3.70          -2.71          Beat
                                  -3.78          
 Dec. 31 2021      -6.00          -8.00          Missed
 Sep. 30 2021      -7.70          -7.20          Beat